Our knowledge of pluripotent stem cell (PSC) biology has advanced to the point where we
now can generate most cells of the human body in the laboratory. PSC-derived …

The discovery of human pluripotent stem cells (hPSCs), including both human embryonic
stem cells and human-induced pluripotent stem cells, has opened up novel paths for a wide …

Existing methods for human induced pluripotent stem cell (hiPSC) cardiac differentiation are
efficient but require complex, undefined medium constituents that hinder further elucidation …

Directed differentiation protocols enable derivation of cardiomyocytes from human
pluripotent stem cells (hPSCs) and permit engineering of human myocardium in vitro …

In mammals, enlargement of the heart during embryonic development is primarily
dependent on the increase in cardiomyocyte numbers. Shortly after birth, however …

Fibrotic rigidification following a myocardial infarct is known to impair cardiac output, and it is
also known that cardiomyocytes on rigid culture substrates show a progressive loss of …

Cardiomyocytes differentiated from human induced pluripotent stem cells (hiPSCs) offer
tremendous potential when used to engineer human tissues for drug screening and disease …

In metazoans, transition from fetal to adult heart is accompanied by a switch in energy
metabolism-glycolysis to fatty acid oxidation. The molecular factors regulating this metabolic …

Cardiomyocytes from human pluripotent stem cells (hPSC-CMs) are increasingly used to
model cardiac disease, test drug efficacy and for safety pharmacology. Nevertheless, a …

During postnatal cardiac development, cardiomyocytes mature and turn into adult ones.
Hence, all cellular properties, including morphology, structure, physiology and metabolism …